ChromaDex Launches Niagen IV, Revolutionizing NAD+ Therapy for Enhanced Cellular Health
- ChromaDex launched Niagen® IV, a pharmaceutical-grade NAD+ therapy available at over 200 Restore Hyper Wellness locations nationwide.
- Clinical studies show Niagen IV can boost NAD+ levels by 20% within three hours while reducing infusion time by 75%.
- ChromaDex collaborates with Restore Hyper Wellness to enhance wellness solutions, reinforcing its leadership in NAD+ research and products.
ChromaDex Advances NAD+ Therapy with Nationwide Launch of Niagen IV
ChromaDex Corp. has made a significant stride in the field of cellular health with the nationwide launch of its pharmaceutical-grade nicotinamide riboside chloride (NRC) product, branded as Niagen® IV. This new intravenous formulation is now available at over 200 Restore Hyper Wellness locations across the United States. The introduction of Niagen IV represents a pivotal moment in the evolution of NAD+ therapy, aimed at enhancing cellular health and extending healthspan for wellness-conscious consumers. As the most effective NAD+ precursor, Niagen plays a crucial role in energizing cellular processes that typically decline due to aging and various lifestyle factors.
The advantages of Niagen IV extend beyond mere availability; clinical studies support its superior efficacy. A recent pilot study demonstrates that Niagen IV can increase whole blood NAD+ levels by 20% just three hours post-infusion, while also reducing infusion time by 75% compared to traditional NAD+ intravenous therapies. This rapid delivery system not only optimizes the benefits of NAD+ but also caters to the growing demand for efficient wellness solutions among consumers. ChromaDex’s CEO, Rob Fried, underscores the company’s commitment to advancing health solutions as he expresses pride in the collaboration with Restore Hyper Wellness, which aligns with their mission to provide safe and effective wellness products.
Restore Hyper Wellness, recognized for its innovative approach to holistic health, enthusiastically embraces the introduction of Niagen IV into its offerings. Dr. Rachele Pojednic, the Director of Scientific Research & Education at Restore, emphasizes the enhanced cellular support provided by this new formulation, positioning it as a superior alternative to traditional NAD+ infusion methods. With the pharmaceutical-grade Niagen compounded and distributed by Wells Pharma of Houston, clinics now have access to a product that meets stringent medical clearance requirements. This partnership not only enhances the therapeutic offerings available at Restore locations but also reinforces ChromaDex’s position as a leading entity in the NAD+ research space.
In addition to its launch, ChromaDex encourages consumers seeking more information about Niagen IV and its availability to visit the respective websites of Restore Hyper Wellness and Niagen. This initiative reflects a broader trend in the wellness industry, where consumers increasingly seek out scientifically backed health solutions to enhance their quality of life.
The introduction of Niagen IV marks a notable development in the realm of intravenous NAD+ therapies, promising to cater to a growing consumer base eager for innovative health solutions that promote longevity and cellular vitality. As the wellness industry continues to evolve, ChromaDex remains at the forefront, committed to providing advanced products that address the needs of health-conscious individuals.